๐ŸŒ EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

๐Ÿงช

Trial Match

Clinical trials test new treatments โ€” sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

๐ŸŽฏ Match trials to me

19 recruiting trials

for Muscular Invasive Bladder Cancer (MIBC)

Adaptive RADiation Therapy With Concurrent Sacituzumab Govitecan (SG) for Muscle Invasive Bladder Cancer NCT05833867Phase 11 site๐Ÿ“ Cleveland Shilpa Gupta, MD ยท Tests: Sacituzumab govitecan, Adaptive Radiotherapy Treatment Expedition With MRI Processing and Optimization for Muscle Invasive Bladder Cancer NCT07067749Phase 31 site๐Ÿ“ Rome University of Rome Tor Vergata ยท Tests: multiparametric magnetic resonance imaging (mpMRI) of the bladder, Transurethral resection of bladder tumour (TURBt), Cโ€ฆ Perioperative Systemic Therapies in Muscle-Invasive Bladder Cancer (GUARDIANS) NCT07855926n/a1 site๐Ÿ“ Munich LMU Klinikum ยท Tests: Perioperative Systemic Therapy Registry Enfortumab Vedotin Plus Pembrolizumab With Selective Bladder Sparing for Treatment of Muscle-invasive Bladder Cancer NCT06809140Phase 25 sites๐Ÿ“ Duarte๐Ÿ“ Indianapolis๐Ÿ“ New York Matthew Galsky ยท Tests: Enfortumab vedotin, Pembrolizumab Erdafitinib Monotherapy or in Combination With Cetrelimab in Muscle-invasive Bladder Cancer Patients With Fibroblast Growth Factor Receptor (FGFR ) Gene Alterations NCT06511648Phase 223 sites๐Ÿ“ Clermont-Ferrand๐Ÿ“ Lyon๐Ÿ“ Paris Spanish Oncology Genito-Urinary Group ยท Tests: Erdafitinib monotherapy, Cetrelimab and Erdafitinib combination EV + Toripalimab vs GC as Neoadjuvant Therapy in Locally Advanced/High-Risk MIBC NCT07647289Phase 21 site๐Ÿ“ Beijing Peking University Third Hospital ยท Tests: enfortumab vedotin (EV), Toripalimab, Gemcitabine (Chemotherapy), Cisplatin Home Intravenous Fluid Infusion After Undergoing Radical Cystectomy NCT07225205NA2 sites๐Ÿ“ Baltimore๐Ÿ“ Baltimore Johns Hopkins University ยท Tests: Intravenous fluids, ERAS A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors NCT05706129Phase 1, Phase 210 sites๐Ÿ“ Melbourne๐Ÿ“ Sydney๐Ÿ“ Clermont-Ferrand Lumara Bio Oncologics GmbH ยท Tests: [68Ga]Ga-DPI-4452, [177Lu]Lu-DPI-4452 Comparison of CT and MR (VI-RADS) Imaging for Local Bladder Cancer Staging NCT07602010n/a1 site๐Ÿ“ Oslo Oslo University Hospital Clinical Study on the Treatment of MIBC Patients With SHR-A2102 Injection Combined With Adebrelimab (SHR-1316) NCT06879145Phase 2, Phase 31 site๐Ÿ“ Shanghai Suzhou Suncadia Biopharmaceuticals Co., Ltd. ยท Tests: SHR-A2102๏ผ›Adebrelimab RC48 Combined With Toripalimab as Neoadjuvant Therapy for Cisplatin Ineligible MIBC Patients NCT06341400Phase 1, Phase 21 site๐Ÿ“ Guangzhou Zhujiang Hospital ยท Tests: DisitamabVedotinForIicction Toripalimab Adjuvant Sacituzumab Govitecan and Nivolumab in Muscle-Invasive Urothelial Carcinoma at High-Risk Recurrence NCT06682728Phase 21 site๐Ÿ“ Orange University of California, Irvine ยท Tests: Sacituzumab Govitecan (SG), Nivolumab Pembrolizumab Monotherapy Following Tri-modality Treatment for Selected Patients With Muscle-invasive Bladder Cancer NCT05072600Phase 21 site๐Ÿ“ Beijing Peking University First Hospital ยท Tests: Pembrolizumab Evaluating the Impact of 18F-FDG-PET-CT on Risk Stratification and Treatment Adaptation for Patients with Muscle Invasive Bladder Cancer NCT04724928Phase 21 site๐Ÿ“ Ghent University Hospital, Ghent ยท Tests: Metastasis directed therapy (MDT), Immunotherapy, Standard of care Neoadjuvant Zanidatamab + Tislelizumab + Chemotherapy for Selective Bladder Preservation in HER2-Positive MIBC NCT07296705Phase 212 sites๐Ÿ“ Fuzhou๐Ÿ“ Fuzhou๐Ÿ“ Putian Fujian Medical University Union Hospital ยท Tests: Zanidatamab, Tislelizumab, Cisplatin, Gemcitabine, Nab-paclitaxel Diagnostic Accuracy of 18F-FDG PET/CT in Muscle-invasive Bladder Cancer NCT07750470n/a1 site๐Ÿ“ Ferrara University Hospital of Ferrara A Multicenter Prospective Cohort Study on Monitoring Recurrence of Urothelial Carcinoma Based on Detection of Urinary Microscopic Residual Disease (MRD) NCT06991868n/a1 site๐Ÿ“ Beijing Peking University First Hospital Validation of a Circulating Tumor DNA Blood Test in Muscle-Invasive Bladder and Upper Tract Urothelial Cancer NCT07756437n/a1 site๐Ÿ“ Ghent AZ Sint-Lucas Gent Bladder Preservation for Patients With Muscle Invasive Bladder Cancer (MIBC) With Variant Histology NCT06417190Phase 21 site๐Ÿ“ Los Angeles Leslie Ballas ยท Tests: Trimodal therapy (TMT) within 45 days of neoadjuvant chemotherapy (NAC)
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy